nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2005 | Controversies–Against

Is whole-body FDG-PET valuable for health screening?

verfasst von: Matthias Weckesser, Otmar Schober

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Excerpt

The idea of using imaging for whole-body cancer screening is alluring. Every nuclear medicine physician working with ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) has observed patients with malignancies unrelated to the referral diagnosis. In a series of such clinically unexpected results, Agress and Cooper showed that ‘incidental’ does not mean ‘negligible’; considerable pathology, especially in the colon, may be detected [1]. These observations suggest the use of FDG-PET for health screening. The justification for such an approach, however, is far from clear, and many prerequisites will have to be met before FDG-PET can be recommended for this purpose. …

Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417–22.

http://www.who.int/cancer/detection/en/

Bayes T. An essay toward solving a problem in the doctrine of chances. Philos Trans R Soc Lond 1763;53:370–418.

Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001;28:1766–9.CrossRef

Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, et al.¹⁸F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989–92.

Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000;30(343):1627–33.CrossRef

Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 2003;23:4357–61.

Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS. The value of¹⁸F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 2003;50:217–21.

Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607–11.CrossRef

10.

Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310–5.CrossRefPubMed

11.

Smith JA, Andreopoulou E. An overview of the status of imaging screening technology for breast cancer. Ann Oncol 2004;15:I18–26.CrossRef

12.

Ell PJ. News and views. Eur J Nucl Med Mol Imaging 2005;31:127–38.

13.

Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998;25:565–74.CrossRef

14.

International Commission on Radiological Protection, Report No. 60 (1991) Recommendations of the International Commission on Radiological Protection.

15.

Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593–97.CrossRefPubMed

Titel: Is whole-body FDG-PET valuable for health screening?
verfasst von: Matthias Weckesser
Otmar Schober
Publikationsdatum: 01.03.2005
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2005
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1775-2

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial

Positron tomographic assessment of androgen receptors in prostatic carcinoma

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death

March 2005

Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines

How does MRI work? An introduction to the physics and function of Magnetic Resonance Imaging. 2003. D. Weishaupt, V.D. Köchli, B.